China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) announced that its Phase III study of QX002N, an anti-IL-17A monoclonal antibody, in ankylosing spondylitis (AS) has met its primary endpoint. The multi-center, randomized, double-blinded, placebo-controlled trial enrolled 641 patients with moderate to severe AS.
Study Results
- Primary Endpoint: Patients receiving 160mg QX002N every four weeks achieved an ASAS40 response rate of 40.4% at week 16, significantly higher than the placebo group’s 18.9% (P<0.0001).
- Secondary Endpoint: The ASAS20 response rate at week 16 was 65.2% for QX002N vs. 41.3% for placebo (P<0.0001).
- Safety: QX002N demonstrated good tolerability during the 16-week double-blind treatment period.-Fineline Info & Tech
Leave a Reply